The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting

Clinical and Translational Science

Volumn 10, Issue 3, 2017, Pages 143-146

  Cavallari, L H ^a   Beitelshees, A L ^b   Blake, K V ^c   Dressler, L G ^d   Duarte, J D ^a   Elsey, A ^a   Eichmeyer, J N ^e   Empey, P E ^f   Franciosi, J P ^c   Hicks, J K ^g   Holmes, A M ^h   Jeng, L J B ^b   Lee, C R ⁱ   Lima, J J ^c   Limdi, N A ^j   Modlin, J ^e   Obeng, A O ^k   Petry, N ^l   Pratt, V M ^m   Skaar, T C ^m   Tuteja, S ⁿ   Voora, D ^o   Wagner, M ^e   Weitzel, K W ^a   Wilke, R A ^p   Peterson, J F ^q   Johnson, J A ^a   more..

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c NEMOURS CHILDREN S CLINIC   (United States)

^d Personalized Medicine Program Mission Cancer Care Mission Health   (United States)

^e St Luke's Mountain States Tumor Institute   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h INDIANA UNIVERSITY   (United States)

ⁱ University of North Carolina   (United States)

^j The University of Alabama at Birmingham   (United States)

^k MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^l NORTH DAKOTA STATE UNIVERSITY   (United States)

^m INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF PENNSYLVANIA   (United States)

^o DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p UNIVERSITY OF SOUTH DAKOTA   (United States)

^q VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19;

CLINICAL DECISION MAKING; COST EFFECTIVENESS ANALYSIS; CYP2C19 GENE; DRUG EFFICACY; ELECTRONIC HEALTH RECORD; EVIDENCE BASED MEDICINE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MEDICAL RESEARCH; ORGANIZATION; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PRACTICE GUIDELINE; REVIEW; ADVERSE DRUG REACTION; ANIMAL; CONSENSUS; COOPERATION; GENETICS; INTERDISCIPLINARY COMMUNICATION; NATIONAL HEALTH ORGANIZATION; ORGANIZATION AND MANAGEMENT; PHARMACOGENETIC VARIANT; PHENOTYPE; RISK ASSESSMENT; STANDARDS; UNITED STATES;

ANIMALS; BIOMEDICAL RESEARCH; CONSENSUS; COOPERATIVE BEHAVIOR; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EVIDENCE-BASED MEDICINE; GENOTYPE; HUMANS; INTERDISCIPLINARY COMMUNICATION; NATIONAL INSTITUTES OF HEALTH (U.S.); PHARMACOGENETICS; PHARMACOGENOMIC VARIANTS; PHENOTYPE; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; UNITED STATES;

EID: 85015295644     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/cts.12456     Document Type: Review

References (6)

1. Relling, M.V. & Klein, T.E. CPIC: Clinical pharmacogenetics implementation consortium of the pharmacogenomics research network. Clin. Pharmacol. Ther. 89, 464–467 (2011).
2. Collins, F.S. & Varmus, H. A new initiative on precision medicine. N. Engl. J. Med. 372, 793–795 (2015).
3. Weitzel, K.W. et al. The IGNITE network: a model for genomic medicine implementation and research. BMC. Med. Genomics. 9, 1 (2016).
4. Scott, S.A. et al. Clinical pharmacogenetics implementation consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin. Pharmacol. Ther. 94, 317–323 (2013).
5. Cavallari L.H. et al. Prospective clinical implementation of CYP2C19-genotype guided antiplatelet therapy after PCI: a multi-site investigation of MACE outcomes in a real-world setting. Circulation. 134, e711–e712 (2016).
6. Oberg, V., Differding, J., Fisher, M., Hines, L. & Wilke, R.A. Navigating pleiotropy in precision medicine: pharmacogenes from trauma to behavioral health. Pharmacogenomics. 17, 499–505 (2016).